BR112013001609A2 - composição farmacêutica, processo para a preparação de uma composição farmacêutica, e, uso de um composto de ciclodextrina - Google Patents

composição farmacêutica, processo para a preparação de uma composição farmacêutica, e, uso de um composto de ciclodextrina

Info

Publication number
BR112013001609A2
BR112013001609A2 BR112013001609A BR112013001609A BR112013001609A2 BR 112013001609 A2 BR112013001609 A2 BR 112013001609A2 BR 112013001609 A BR112013001609 A BR 112013001609A BR 112013001609 A BR112013001609 A BR 112013001609A BR 112013001609 A2 BR112013001609 A2 BR 112013001609A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
preparing
hydrogen
cyclodextrin compound
alkyl
Prior art date
Application number
BR112013001609A
Other languages
English (en)
Inventor
Szlak-Freier Alda
Tardt Axel
Hauptmeier Bernhard
Strehl Diana
Kiehm Kevin
Plitt Patrick
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of BR112013001609A2 publication Critical patent/BR112013001609A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/305—Mercury compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

composição farmacêutica, processo para a preparação de uma composição farmacêutica, e, uso de um composto de ciclodextrina. compsoições farmacêuticas contendo um composto da fórmula (i) em que os radicais indicam, por exemplo: r ^1^ é hidrogênio ou alquila c ~1~-c ~8~; r ^2^ é hidrogênio ou alquila c ~1~-c ~8~; r ^3^ é hidrogênio ou alquila c ~1~-c ~8~; r ^4^ é oh; r ^5^ é hidrogênio e um derivado de ciclodextrina farmaceuticamente aceitável pode ser usado para a preparação de formulações oftálmicas.
BR112013001609A 2010-07-22 2011-07-06 composição farmacêutica, processo para a preparação de uma composição farmacêutica, e, uso de um composto de ciclodextrina BR112013001609A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36653810P 2010-07-22 2010-07-22
EP10170397 2010-07-22
PCT/EP2011/061356 WO2012010415A1 (en) 2010-07-22 2011-07-06 Pharmaceutical composition containing a tryptophan derivative

Publications (1)

Publication Number Publication Date
BR112013001609A2 true BR112013001609A2 (pt) 2017-04-04

Family

ID=42727444

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013001609A BR112013001609A2 (pt) 2010-07-22 2011-07-06 composição farmacêutica, processo para a preparação de uma composição farmacêutica, e, uso de um composto de ciclodextrina

Country Status (13)

Country Link
US (2) US20130197053A1 (pt)
EP (1) EP2595625B1 (pt)
JP (1) JP6038786B2 (pt)
KR (1) KR20130102037A (pt)
CN (1) CN103052387A (pt)
AR (1) AR082328A1 (pt)
AU (1) AU2011281837A1 (pt)
BR (1) BR112013001609A2 (pt)
CA (1) CA2805968A1 (pt)
MX (1) MX2013000855A (pt)
RU (1) RU2013107761A (pt)
TW (1) TW201216960A (pt)
WO (1) WO2012010415A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021021267A2 (pt) * 2019-04-24 2021-12-21 Galimedix Therapeutics Inc Compostos de indol para uso na neurorrestauração
TWI775154B (zh) * 2019-09-23 2022-08-21 美商格利麥迪克斯治療公司 (r)-2-[2-胺基-3-(吲哚-3-基)丙醯基胺基]-2-甲基丙酸之新穎多晶型及其用途
WO2021222888A1 (en) * 2020-05-01 2021-11-04 University Of Southern California Cyclodextrin based anti-microbial therapy
BR112022023734A2 (pt) * 2020-05-24 2023-02-07 Galimedix Therapeutics Inc Formas cristalinas de solvatos de derivados de triptofano, composições que as compreendeem e usos das mesmas
CN115340615B (zh) * 2022-08-12 2023-05-02 同济大学 一种基于环糊精-氨基酸的荧光分子及其合成方法与应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
DE3615710A1 (de) * 1986-05-09 1987-11-26 Hoechst Ag Zubereitungen fuer die synthese von prostaglandinen und hydroxyfettsaeuren in biologischen systemen
US7781396B2 (en) 2002-01-31 2010-08-24 Tel Aviv University Future Technology Development L.P. Peptides directed for diagnosis and treatment of amyloid-associated disease
US20070021345A1 (en) * 2003-06-30 2007-01-25 Ehud Gazit Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
US20050244472A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
US7893040B2 (en) * 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
AR067746A1 (es) * 2007-08-02 2009-10-21 Otsuka Pharma Co Ltd Un medicamento para tratar glaucoma que comprende como elemento activo compuesto de ciclodextrina - clatrato de cilostazol
EP2044951A1 (en) * 2007-10-02 2009-04-08 Merz Pharma GmbH & Co. KGaA The use of substances for the treatment of loss of eyesight in humans with glaucoma and other degenerative eye diseases
ITRM20080182A1 (it) 2008-04-07 2009-10-08 Medivis S R L Preparato oftalmico a base di dorzolamide e latanoprost per il trattamento topico del glaucoma.
TW201006463A (en) 2008-06-26 2010-02-16 Merz Pharma Gmbh & Co Kgaa Pharmaceutical compositions comprising aminocyclohexane derivatives
US20100311688A1 (en) * 2009-06-05 2010-12-09 Aciex Therapeutics, Inc. Ophthalmic formulations, methods of manufacture, and methods of using same

Also Published As

Publication number Publication date
MX2013000855A (es) 2013-02-27
JP2013532638A (ja) 2013-08-19
US20180118682A1 (en) 2018-05-03
CN103052387A (zh) 2013-04-17
CA2805968A1 (en) 2012-01-26
AR082328A1 (es) 2012-11-28
KR20130102037A (ko) 2013-09-16
EP2595625A1 (en) 2013-05-29
WO2012010415A1 (en) 2012-01-26
EP2595625B1 (en) 2016-04-20
AU2011281837A1 (en) 2013-03-14
US20130197053A1 (en) 2013-08-01
RU2013107761A (ru) 2014-08-27
TW201216960A (en) 2012-05-01
JP6038786B2 (ja) 2016-12-07

Similar Documents

Publication Publication Date Title
NI201200184A (es) Morfolinopirimidinas y su uso en terapia
UY31906A (es) Derivados de n-cicloalquil-3-fenilnicotinamida que inhiben pgds, sus composiciones, su uso para el tratamiento por ejemplo de afecciones alérgicas y respiratorias.
UY31831A (es) Derivados de indazoles sustituidos con fenilo o piridinilo
ECSP10010693A (es) Compuestos pirazólicos 436
BR112014000713A2 (pt) derivados de indol substituído como moduladores de gama secretase
BR112013016856A2 (pt) composto, uso de um composto, composição farmacêutica e produto farmacêutico
ECSP099750A (es) Imidazoquinolinas con propiedades inmunomoduladoras
SV2011003802A (es) Derivados de triazol utiles para el tratamiento de enfermedades
BR112013018601A2 (pt) composto, uso de composto, composição farmacêutica, e, produto farmacêutico
BR112014009102A2 (pt) compostos químicos
UY30824A1 (es) Nuevos derivados de idazolil éster o amida, composiciones farmacéuticas conteniéndolas, procesos de preparacion y aplicaciones.
BR112015031878A2 (pt) composição farmacêutica
GEP20227397B (en) Inhibitors of influenza viruses replication
BR112013001609A2 (pt) composição farmacêutica, processo para a preparação de uma composição farmacêutica, e, uso de um composto de ciclodextrina
BRPI0916069B8 (pt) composto, usos de um composto e composição farmacêutica
BR112014001083B8 (pt) Composto, processo para a preparação de um composto, composição farmacêutica, uso da composiçâo farmacêutica e uso do composto
HK1146049A1 (en) Isoxazole derivatives as modulators of 11-beta-hydroxysteroid dehydrogenase type 1
BRPI0718436B8 (pt) compostos antagonistas do receptor b1 da bradicinina derivados de fenilsulfamoilbenzamida, processo para preparar os mesmos, uso dos mesmos e composição farmacêutica
BR112018069712A2 (pt) composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, método para administração de uma quantidade eficaz de uma composição farmacêutica, e, inibidor de tnf-a.
UY32055A (es) Derivados sustituidos de la 5-Halo-N2-[sustituido](1-metil-1H-imidazol-4-il)pirimidin-2,-diamina y sus sales farmacéuticamente aceptables, procesos de preparación, composiciones y aplicaciones.
BR112015021133B8 (pt) mistura de compostos, processo para produzir uma mistura de compostos e limpar superfícies duras ou fibras, formulação aquosa, e, uso de misturas de compostos
UY30356A1 (es) Derivados de 3-halo-n-(2.(4-fluorofenil)-4-oxobutil)-n-metil-5-(trifluorometil)benzamida y composiciones de los mismos.
BR112014015430A2 (pt) formulação oftálmica
BR112015018200A2 (pt) composição mastigável para administração oral e processo para preparar a mesma
BR112013027395A2 (pt) inibidores de 17alfa-hidroxilase/c17,20-liase

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]